Delivery Order SPE2DB20D9127-SPE2DB24FPQA6
- Not listed
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $4,642.20 firm fixed-price delivery order is for the provision of Xolair 150 mg/mL syringes, a specialized pharmaceutical product, with a period of performance through January 25, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA to supply a...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order valued at $9,284.40. The contract was awarded by the Defense Logistics Agency (DLA) and has no set-aside designation. It is part of the DLA's larger SPE2DB Indefinite Delivery Contract (IDC) valued at up to $499,999,999, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of...
- This federal contract award is a delivery order for Xolair 150 mg/ml syringes, awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,547.40 firm fixed-price contract has an ultimate completion date of April 18, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Xolair 150 mg/ml syringes. The $9,284.40 firm fixed-price delivery order was issued by the Defense Logistics Agency's (DLA) Medical Supply Chain division, which supports the recurring pharmaceutical needs of Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare facilities nationwide. DMS Pharmaceutical Group holds a significant...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $9,671.25 firm fixed-price delivery order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGEML, with a completion date of June 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,547.40 firm fixed-price delivery order is for the supply of Xolair 150 mg/ml syringes and has a total completion date of January 14, 2025. DMS Pharmaceutical Group holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a delivery order under the DLA's SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The award, valued at $98,364.00, is for the provision of Xolair 150 mg/mL syringes to support the medical supply needs of military healthcare facilities. As a key supplier in the federal pharmaceutical supply chain, DMS...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $74,275.20 firm fixed-price delivery order covers the supply of Xolair 150 mg/1.2 ml powder vials to support the recurring medical needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which allows the agency to issue...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $7,737.00 firm fixed-price delivery order is for the supply of Xolair 150 mg/ml syringes, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain program. The $6,189.60 firm fixed-price delivery order is for the supply of Xolair 150 mg/ml syringes, a specialty medication, to support the recurring medical needs of military healthcare facilities. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB24FPQA6Delivery Order
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a delivery order valued at $37,137.60. The contract provides for the delivery of Xolair 150 mg/mL syringes to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The contract does not have a set-aside designation, enabling DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.1k | 2/29/24 |